Reference health
Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
31/31 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
7 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 31 checked references that resolve
resolves10.1002/(SICI)1096-9098(200001)73:1<17::AID-JSO5>3.0.CO;2-2
c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues
resolves10.1093/jnci/93.15.1141
Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer
resolves10.1056/NEJM200103153441101
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
resolves10.1038/modpathol.3880503
Amplification of Her-2/neu Gene in Her-2/neu-Overexpressing and -Nonexpressing Breast Carcinomas and Their Synchronous Benign, Premalignant, and Metastatic Lesions Detected by FISH in Archival Material
resolves10.1093/annonc/mdf252
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
resolves10.1023/B:BREA.0000004378.15859.51
Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer
resolves10.1002/path.1592
Change of HER‐2/neu status in a subset of distant metastases from breast carcinomas
resolves10.1038/sj.bjc.6601881
HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review
resolves10.1038/sj.bjc.6602738
Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
resolves10.1002/cncr.20987
Comparison of <i>HER‐2</i> status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma
resolves10.1007/s10549-006-9300-2
Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis
resolves10.1093/annonc/mdp028
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?
resolves10.1007/s10549-010-1029-2
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
resolves10.1186/bcr2771
Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)
resolves10.1200/JCO.2003.03.124
Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study
resolves10.1200/JCO.2005.02.8886
Docetaxel, Cisplatin, and Trastuzumab As Primary Systemic Therapy for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced Breast Cancer
resolves10.1158/1078-0432.CCR-06-1304
Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer
resolves10.1158/1078-0432.CCR-09-1735
Loss of <i>HER2</i> Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
resolves10.1002/cncr.10456
HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process
resolves10.1016/S0039-6109(03)00034-3
Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual
resolves10.1038/nature08989
Genome remodelling in a basal-like breast cancer metastasis and xenograft
resolves10.1002/ijc.2910630113
Clonal heterogeneity in breast cancer: Karyotypic comparisons of multiple intra—and extra—tumorous samples from 3 patients
resolves10.1093/annonc/mdp263
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
resolves10.1634/theoncologist.2010-0059
Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis
resolves10.1007/s10549-004-6275-8
Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab
resolves10.1200/JCO.2005.03.4744
<i>HER2</i> Testing by Local, Central, and Reference Laboratories in Specimens From the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial
resolves10.1158/1078-0432.CCR-05-0636
Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials
resolves10.1200/JCO.2007.14.8197
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
resolves10.1093/jnci/94.11.852
Real-World Performance of HER2 Testing--National Surgical Adjuvant Breast and Bowel Project Experience
The 7 references without a DOI — listed, not checked
no DOI — not checkedB1
no DOI — not checkedB4
no DOI — not checkedB13
no DOI — not checkedB25
no DOI — not checkedB26
no DOI — not checkedB28
no DOI — not checkedB37
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1200/jco.2010.33.8889"><img src="https://citestamp.com/citestamped/10.1200/jco.2010.33.8889/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1200/jco.2010.33.8889)